Cintas Corporation vs Intuitive Surgical, Inc. — how do they compare? Cintas Corporation trades at $202.19 (market cap $79.86B), while Intuitive Surgical, Inc. trades at $426.13 (market cap $146.76B). The key difference: Intuitive Surgical, Inc. is the larger of the two by market cap, and Cintas Corporation pays a 1.03% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Intuitive Surgical, Inc. for 84 Days on average.
| CTAS | ISRG | |
|---|---|---|
Market Cap | $79.86B | $146.76B |
Volume | 1,323,583 | 2,529,814 |
Sector | Industrials | Health |
52-Week High | $216.53 | $592.85 |
52-Week Low | $163.55 | $332.02 |
Typical Hold Time | 124 Days | 84 Days |
Enterprise Value | $82.33B | $141.54B |
Dividend Yield | 1.03% | — |
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $201.87, up 2.37% today, reflecting strong momentum after Q1 2027 earnings beat. The stock shows bullish technical signals with support near $195 and resistance at $200. Fundamentals are robust with revenue growth to $10.34B in 2025, net margin of 17.82%, and rising profitability. Recent news highlights raised guidance and record quarterly revenue exceeding $3B, signaling operational strength.
Outlook remains positive driven by organic growth and margin expansion, but high valuation multiples (P/E 39.67) pose a risk if growth slows. Analyst consensus is Moderate Buy with a $234.60 price target, implying 16% upside. Key risks include economic sensitivity and competitive pressures in uniform services.
Intuitive Surgical (ISRG) trades at $424.58, up 2.43% with strong bullish momentum. The stock shows robust fundamentals with revenue growing from $6.2B in 2022 to $10.1B in 2025 and net profit margins exceeding 28%. Recent earnings consistently beat expectations, with Q2 2026 EPS of $2.80 surpassing the $2.48 forecast. Technical indicators show bullish moving averages with support at $410 and resistance at $419. Analyst consensus remains strongly positive with 70% buy ratings and a $480.78 price target.
ISRG maintains a dominant position in robotic surgery with expanding international growth offsetting China headwinds. The primary investment opportunity lies in continued procedure growth and da Vinci 5 adoption, though risks include competitive pressures and affordability concerns. With strong cash flow generation and institutional support, the stock presents upside potential despite premium valuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →